SCHEMBL4576643

SCHEMBL4576643

CC(C)(C)OC(=O)CCCCCl

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.41
HDAC8 Q9BY41 3/20 0.39
HDAC1 Q13547 2/20 0.37
HDAC2 Q92769 2/20 0.37
HDAC6 Q9UBN7 2/20 0.37
TSHR P16473 2/20 0.36
HDAC3 O15379 1/20 0.34
DGKA P23743 1/20 0.33
RECQL P46063 1/20 0.33
STING1 Q86WV6 1/20 0.33
FAAH O00519 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
CYP2D6 P10635 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA7 P43166 1/20 0.32
LMNA P02545 2/20 0.31
DGAT1 O75907 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28898948 0.98 EPHX2 (0.43) EPHX2HDAC8HDAC1HDAC2HDAC6
SCHEMBL417782 0.93 EPHX2 (0.39) EPHX2HDAC8HDAC1HDAC2HDAC6
SCHEMBL18804573 0.89 EPHX2 (0.39) EPHX2HDAC8HDAC1HDAC2HDAC6
SCHEMBL18804554 0.89 EPHX2 (0.39) EPHX2HDAC8HDAC1HDAC2HDAC6
SCHEMBL134923 0.89 EPHX2 (0.46) EPHX2HDAC8HDAC1HDAC2HDAC6
SCHEMBL18788286 0.88 EPHX2 (0.38) EPHX2HDAC8HDAC1HDAC2HDAC6
SCHEMBL25920499 0.88 EPHX2 (0.38) EPHX2HDAC8HDAC1HDAC2HDAC6
SCHEMBL18804567 0.88 EPHX2 (0.38) EPHX2HDAC8HDAC1HDAC2HDAC6
SCHEMBL14482131 0.86 EPHX2 (0.49) EPHX2HDAC8HDAC1HDAC2HDAC6
SCHEMBL14482719 0.86 EPHX2 (0.49) EPHX2HDAC8HDAC1HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4655069-A1 PYRIDAZINES AS SARM1 INHIBITORS Disarm Therapeutics, Inc. (US) 2025-12-03 EP disclosed
WO-2024158775-A1 PYRIDAZINES AS SARM1 INHIBITORS DISARM THERAPEUTICS, INC. (US) 2024-08-02 WO disclosed
WO-2020054874-A1 PHOTOPOLYMERIZATION SENSITIZER 川崎化成工業株式会社 2020-03-19 WO disclosed
US-20080269240-A1 Novel Adenine Compound Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) 2008-10-30 US disclosed
EP-1939199-A1 NOVEL ADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269240-A1 Novel Adenine Compound ADORA1, ADORA2A, ADORA3 EPHX2 2136/4885HDAC8 1460/4885HDAC1 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.